サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1132593

リアルワールドエビデンス (RWE) ソリューションの米国市場：コンポーネント別［データセット（臨床、請求、薬局、統合）、サービス］、用途別（市場アクセス、腫瘍学、神経学）、エンドユーザー別（製薬、医療提供者）の予測（～2029年）

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029
出版日: | 発行: Meticulous Research | ページ情報: 英文 103 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
リアルワールドエビデンス (RWE) ソリューションの米国市場：コンポーネント別［データセット（臨床、請求、薬局、統合）、サービス］、用途別（市場アクセス、腫瘍学、神経学）、エンドユーザー別（製薬、医療提供者）の予測（～2029年）
出版日: 2022年06月10日
発行: Meticulous Research
ページ情報: 英文 103 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国のリアルワールドエビデンス (RWE) ソリューションの市場規模は、2022年から2029年の間に13.1％のCAGRで成長し、2029年には22億2,000万米ドルに達すると予測されています。市場の成長を後押しする主な要因には、慢性疾患および感染症の発生率の増加、医薬品開発の遅れとそれに伴う開発コストの増加、個別化医療への注目の高まり、量から価値に基づく医療へのシフト、医療におけるビッグデータの急増などが挙げられます。

当レポートでは、米国のリアルワールドエビデンス (RWE) ソリューション市場を調査しており、市場の概要、市場規模や予測、動向、促進要因・抑制要因、競合情勢、コンポーネント別・用途別・エンドユーザー別の分析、および企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場エコシステム
  • 通貨

第2章 調査手法

  • 調査プロセス
  • データ収集と検証
    • 2次調査
    • 1次調査
  • 市場評価
    • 市場規模予測
    • 市場シェア分析
  • 調査の前提条件
  • 調査の制限

第3章 エグゼクティブサマリー

第4章 市場の洞察

  • 市場概要
  • 促進要因
    • 慢性疾患および感染症の負担の増大
    • 個別化医療への関心の高まり
    • 医薬品開発の遅れとそれに伴う開発費の増加
    • 価値に基づくケアへのシフト
    • 医療において急速に拡大するビッグデータ
  • 抑制要因
    • リアルワールド研究に頼ることへのためらい
  • 機会
    • エンドツーエンドのRWEサービスへの関心の高まり
    • RWEにおけるウェアラブルデバイスと人工知能の採用の増加
  • 課題
    • RWEを開発するための標準化された方法の欠如
  • 主要な市場動向
    • 医薬品の開発と商業化におけるRWEの採用の拡大
    • 合併数の増加
    • RWEに基づく患者転帰の改善と価値創造
  • 米国のリアルワールドエビデンス (RWE) ソリューション市場へのCOVID-19の影響評価

第5章 規制分析：米国のリアルワールドエビデンス（RWE）ソリューション市場

第6章 価格設定モデル（EMR/ゲノム/統合データセット）

  • イントロダクション
  • 患者カルテ毎の支払い（数量ベースの価格設定）
  • 従量課金制（金額ベースの価格設定）
  • 年間会費

第7章 米国のリアルワールドエビデンス (RWE) ソリューション市場：コンポーネント別

  • イントロダクション
  • データセット
    • 異種データセット
    • 統合データセット
  • コンサルティング・分析

第8章 米国のリアルワールドエビデンス (RWE) ソリューション市場：用途別

  • イントロダクション
  • 市場アクセスと償還/適用範囲の決定
  • 医薬品の開発と承認
    • 腫瘍学
    • 神経学
    • 免疫学
    • 心血管疾患
    • その他の治療領域
  • 医療機器の開発と承認
  • 市販後調査
  • その他

第9章 米国のリアルワールドエビデンス (RWE) ソリューション市場：エンドユーザー別

  • イントロダクション
  • 製薬、バイオテクノロジー、医療機器企業
  • 医療費支払者
  • 医療提供者
  • その他

第10章 競合情勢

  • イントロダクション
  • 主要な成長戦略
  • 競合ベンチマーキング
  • 市場シェア分析（2020年）
    • IQVIA Holdings, Inc.
    • ICON plc
    • PPD, Inc.

第11章 企業プロファイル（事業概要、財務概要、ソリューションポートフォリオ、戦略的展開）

  • Anthem, Inc.
  • Clinigen Group plc.
  • Cognizant Technology Solutions Corporation
  • ICON plc
  • IQVIA HOLDINGS INC.
  • Oracle Corporation
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • PPD, Inc.
  • SAS Institute Inc.
  • UnitedHealth Group Incorporated
  • Flatiron Health, Inc.
図表

List of Tables

  • Table 1 U.S. Real-World Evidence Solutions Market Drivers: Impact Analysis (2022-2029)
  • Table 2 Total Per-Study Cost (In Usd Million), by Phase and Therapeutic Area
  • Table 3 Sources of Healthcare Data
  • Table 4 U.S. Real-World Evidence Solutions Market Restraints: Impact Analysis (2022-2029)
  • Table 5 Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
  • Table 6 U.S. Real-World Evidence Solutions Market Size, by Component, 2012-2029 (USD Million)
  • Table 7 U.S. Real-World Evidence Datasets Market Size, by Type, 2020-2029 (USD Million)
  • Table 8 U.S. RWE Disparate Datasets Market Size, by Type, 2020-2029 (USD Million)
  • Table 9 U.S. Real-World Evidence Solutions Market Size, by Application, 2020-2029 (USD Million)
  • Table 10 U.S. RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 11 Estimated Number of New Cancer Cases in the U.S. (2019-2023)
  • Table 12 Medical Costs Associated With Cardiovascular Diseases (2010-2030) (USD Billion)
  • Table 13 Other Therapeutic Areas: Drugs in the R&D Pipeline
  • Table 14 U.S. RWE Solutions Market Size, by End User, 2020-2029 (USD Million)
  • Table 15 Recent Developments, by Company, 2018-2022

List of Figures

  • Figure 1 Key Stakeholders
  • Figure 2 Research Process
  • Figure 3 Key Secondary Sources
  • Figure 4 Primary Research Techniques
  • Figure 5 Key Executives Interviewed
  • Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 7 Market Size Estimation
  • Figure 8 U.S. Real-World Evidence Solutions Market, by Component, 2022 Vs. 2029 (USD Million)
  • Figure 9 U.S. Real-World Evidence Solutions Market, by Application, 2022 Vs. 2029 (USD Million)
  • Figure 10 U.S. Real-World Evidence Solutions Market, by End User, 2022 Vs. 2029 (USD Million)
  • Figure 11 Market Dynamics
  • Figure 12 Number of People in the U.S. With Chronic Conditions (2000-2030)
  • Figure 13 Percentage of Personalized Medicines Approved (2015-2020)
  • Figure 14 U.S. Real-World Evidence Solutions Market Size, by Component, 2022-2029 (USD Million)
  • Figure 15 U.S.: Number of E-Prescriptions, 2013-2020 (Billions)
  • Figure 16 U.S. Real-World Evidence Solutions Market Size, by Application, 2022-2029 (USD Million)
  • Figure 17 Dalys of Neurological Disorders in the U.S., 2010-2021 (In Thousands)
  • Figure 18 U.S.: Hepatitis A Virus (HAV) Infections, 2013-2020
  • Figure 19 U.S. Real-World Evidence Solutions Market Size, by End User, 2022-2029 (USD Million)
  • Figure 20 U.S. Pharmaceutical R&D Spending, 1980-2019 (USD Billion)
  • Figure 21 Key Growth Strategies Adopted by Leading Players (2018-2022)
  • Figure 22 U.S. Real-World Evidence Solutions: Competitive Benchmarking
  • Figure 23 Market Share Analysis: U.S. Real-World Evidence Solutions Industry (2021)
  • Figure 24 Anthem, Inc.: Financial Overview (2021)
  • Figure 25 Clinigen Group plc: Financial Overview (2021)
  • Figure 26 Cognizant Technology Solutions Corporation: Financial Overview (2021)
  • Figure 27 ICON plc: Financial Overview (2021)
  • Figure 28 IQVIA HOLDINGS INC.: Financial Overview (2021)
  • Figure 29 Oracle Corporation: Financial Overview (2021)
  • Figure 30 PerkinElmer, Inc.: Financial Overview (2022)
  • Figure 31 PPD, Inc.: Financial Overview (2020)
  • Figure 32 SAS Institute Inc.: Financial Overview (2021)
  • Figure 33 UnitedHealth Group Incorporated.: Financial Overview (2021)
目次
Product Code: MRHC - 104556

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers)- Forecast to 2029

The U.S. RWE solutions market is expected to grow at a CAGR of 13.1% from 2022 to 2029 to reach $2.22 billion by 2029

Following a thorough secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities

Growing incidence of chronic & infectious diseases, delays in drug development and the subsequent increase in development costs, rising focus towards personalized healthcare, a shift from volume to value-based care, and rapidly growing big data in healthcare are the key factors driving steady growth in the U.S. RWE solutions market. Further, significant opportunities for existing market players and new entrants are provided by rising focus on end-to-end RWE services, and rising adoption of wearable devices and AI in RWE

Based on component, in 2022, the datasets segment is expected to command the largest share in the market. Real-world data (RWD) are derived from various sources associated with outcomes in a heterogeneous patient population in real-world settings. Datasets are present in a secondary format on which retrospective studies are conducted to generate real-world evidence. This real-world evidence provides meaningful insights into unmet needs and the clinical and economic impacts on patients and healthcare systems. It also determines the outcomes based on much larger data samples, reduces costs, and improves the efficiency of clinical trials.

Based on application, the drug development & approvals segment is expected to show the fastest growth rate in the forecast period. Factors attributing towards the growth of this segment are increasing demand for real-world data and real-world evidence to accelerate drug discovery and development, and increasing investments by biopharmaceutical companies in R&D.

In the field of drug development, quality-of-life metrics, and Patient-Reported Outcome Measures (PROMs) are now becoming common elements in clinical trials. The evidence generated from real-world data is regularly utilized to inform aspects of drug development. The role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs.

Based on end user, the pharmaceutical & medical device companies segment is expected to show the fastest growth rate in the forecast period. The growth of this segment is primarily attributed to the increasing importance of RWE studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

The cost of developing a new drug was more than ~USD 2,600 million in 2020 compared to USD 802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face.

The key companies operating in the U.S. RWE solutions market are Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA HOLDINGS INC. (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).

Scope of the Report

U.S. RWE Solutions Market, by Component

  • Datasets
  • Disparate Datasets
  • EMR/EHR/Clinical Data
  • Claims & Billing Data
  • Pharmacy Data
  • Product/Disease Registries Data
  • Other Disparate Datasets
  • Integrated Datasets
  • Consulting and Analytics

(Note - Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

U.S. RWE Solutions Market, by Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
  • Oncology
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Other Therapeutic Areas
  • Post Market Surveillance
  • Medical Device Development & Approvals
  • Clinical and Regulatory Decision-Making

(Note - Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases)

U.S. RWE Solutions Market, by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users

(Note - Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
      • 2.3.1.1. Bottom-Up Approach
      • 2.3.1.2. Top-Down Approach
      • 2.3.1.3. Growth Forecast
    • 2.3.2. Market Share Analysis
  • 2.4. Assumptions for the Study
  • 2.5. Limitations for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Market Overview
  • 4.2. Drivers
    • 4.2.1. Growing Burden of Chronic and Infectious Diseases
    • 4.2.2. Rising Focus Towards Personalized Healthcare
    • 4.2.3. Delays in Drug Development and the Subsequent Increase in Development Costs
    • 4.2.4. Shift Towards Value-Based Care
    • 4.2.5. Rapidly Growing Big Data in Healthcare
  • 4.3. Restraints
    • 4.3.1. Reluctance to Rely on Real-World Studies
  • 4.4. Opportunities
    • 4.4.1. Rising Focus on End-to-End RWE Services
    • 4.4.2. Rising Adoption of Wearable Devices and Artificial Intelligence in RWE
  • 4.5. Challenges
    • 4.5.1. Lack of Standardized Methodologies to Develop RWE
  • 4.6. Key Market Trends
    • 4.6.1. Growing Adoption of RWE in Drug Development and Commercialization
    • 4.6.2. Rising Number of Consolidations
    • 4.6.3. Improved Patient Outcomes and Value Creation from Real-World Evidence
  • 4.7. Impact Assessment of COVID-19 on the U.S. RWE Solutions Market

5. Regulatory Analysis - U.S. Real-World Evidence (RWE) Solutions Market

6. Pricing Models (EMR/Genomic/Integrated Datasets)

  • 6.1. Introduction
  • 6.2. Pay Per Patient Record (Volume-Based Pricing)
  • 6.3. Pay Per Usage (Value-Based Pricing)
  • 6.4. Annual Subscription

7. U.S. Real-World Evidence Solutions Market, by Component

  • 7.1. Introduction
  • 7.2. Datasets
    • 7.2.1. Disparate Datasets
      • 7.2.1.1. EMR/EHR/Clinical Data
      • 7.2.1.2. Claims & Billing Data
      • 7.2.1.3. Pharmacy Data
      • 7.2.1.4. Product/Disease Registries Data
      • 7.2.1.5. Other Disparate Datasets
    • 7.2.2. Integrated Datasets
  • 7.3. Consulting & Analytics

8. U.S. Real-World Evidence Solutions Market, by Application

  • 8.1. Introduction
  • 8.2. Market Access & Reimbursement/Coverage Decisions
  • 8.3. Drug Development & Approvals
    • 8.3.1. Oncology
    • 8.3.2. Neurology
    • 8.3.3. Immunology
    • 8.3.4. Cardiovascular Diseases
    • 8.3.5. Other Therapeutic Areas
  • 8.4. Medical Device Development & Approvals
  • 8.5. Post-Market Surveillance
  • 8.6. Other Applications

9. U.S. Real-World Evidence Solutions Market, by End User

  • 9.1. Introduction
  • 9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
  • 9.3. Healthcare Payers
  • 9.4. Healthcare Providers
  • 9.5. Other End Users

10. Competitive Landscape

  • 10.1. Introduction
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Market Share Analysis (2020)
    • 10.4.1. IQVIA Holdings, Inc. (U.S.)
    • 10.4.2. ICON plc (Ireland)
    • 10.4.3. PPD, Inc. (U.S.)

11. Company Profiles (Business Overview, Financial Overview, Solution Portfolio, Strategic Developments)

  • 11.1. Anthem, Inc.
  • 11.2. Clinigen Group plc.
  • 11.3. Cognizant Technology Solutions Corporation
  • 11.4. ICON plc
  • 11.5. IQVIA HOLDINGS INC.
  • 11.6. Oracle Corporation
  • 11.7. PAREXEL International Corporation
  • 11.8. PerkinElmer, Inc.
  • 11.9. PPD, Inc.
  • 11.10. SAS Institute Inc.
  • 11.11. UnitedHealth Group Incorporated
  • 11.12. Flatiron Health, Inc.